Independent
Tenure on this board
4.5 yrs
Also a director at
Ibio Inc (IBIO)Lenz Therapeutics Inc (LENZ)
Meeting calendar
CTNM · Annual meeting · Friday, June 26, 2026
Contineum Therapeutics Inc
3 nominees · 2 ballot items.
Stockholders are asked to elect three Class II directors (Evert Schimmelpennink, Lori M. Lyons‑Williams, and Diego Miralles, M.D.) to serve until 2029 and to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Market cap
$524M
1Y TSR
+204.9%
Board grade
C-
Record date
Apr 27, 2026
Filing
DEF 14A
Meeting concluded · Jun 26, 2026
Follow how the vote landed and what changed on Contineum Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect Evert Schimmelpennink, Lori M. Lyons‑Williams and Diego Miralles, M.D. as Class II directors to serve until the 2029 annual meeting of stockholders or until their successors are elected and qualified.
- 2
Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026
ManagementBoard: FORRatify the appointment of Ernst & Young LLP as Contineum Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
6.0 yrs
Not independent
Tenure on this board
1.3 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 7.6% | 2,841,334 | $37M |
| 2 | JANUS HENDERSON GROUP PLC | 7.3% | 2,734,836 | $36M |
| 3 | JOHNSON JOHNSON | 5.3% | 1,979,173 | $26M |
| 4 | FRANKLIN RESOURCES INC | 4.9% | 1,839,227 | $24M |
| 5 | BALYASNY ASSET MANAGEMENT L.P. | 4.5% | 1,685,635 | $22M |
| 6 | MILLENNIUM MANAGEMENT LLC | 4.1% | 1,535,449 | $20M |
| 7 | BAKER BROS. ADVISORS LP | 3.8% | 1,420,838 | $19M |
| 8 | RA CAPITAL MANAGEMENT, L.P. | 3.5% | 1,296,012 | $17M |
| 9 | PERCEPTIVE ADVISORS LLC | 3.4% | 1,255,592 | $16M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 1,214,173 | $16M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Contineum Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$724M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.3B
Reference
Frequently asked questions
- When is the Contineum Therapeutics Inc 2026 annual meeting?
- Contineum Therapeutics Inc (CTNM) holds its 2026 annual shareholder meeting on Friday, June 26, 2026.
- What is the record date for the Contineum Therapeutics Inc 2026 meeting?
- The record date for the Contineum Therapeutics Inc 2026 meeting is Monday, April 27, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Contineum Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Contineum Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Contineum Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Contineum Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.